Sequential Drug Treatment for High-Risk Triple-Negative Breast Cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new treatment approach using capecitabine (a chemotherapy pill) given in a specific sequence for women with aggressive triple-negative breast cancer who do not have BRCA gene mutations. The goal is to see if this approach can reduce the chance of cancer returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Female, age 18 or older
- Diagnosed with triple-negative breast cancer (cancer cells lack three specific markers: ER, PR, and HER2)
- Do not have BRCA1 or BRCA2 gene mutations
- Have lymph node involvement and either didn't respond fully to prior chemotherapy or need adjuvant treatment after surgery
- No evidence of cancer spread to distant organs (checked by imaging within 3 months)
- Heart and organ function are adequate; able to take oral medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, given before surgery for triple-negative breast cancer (a type of breast cancer that lacks three common markers). The study aims to see if this treatment can shrink tumors and improve outcomes.
Hear when a new Adjuvant Drug Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.